SHANDONG XINHUA (00719): Nimodipine Tablets Pass Generic Drug Consistency Evaluation

SHANDONG XINHUA (00719) announced that the Company recently received the "Drug Supplementary Application Approval Notice" for Nimodipine Tablets issued upon approval by the National Medical Products Administration. The product has passed the generic drug quality and efficacy consistency evaluation. In July 2025, Shandong Xinhua Pharmaceutical submitted the consistency evaluation application materials for Nimodipine Tablets to the Center for Drug Evaluation (CDE) of the National Medical Products Administration, and the application was accepted. In October 2026, the "Drug Supplementary Application Approval Notice" was obtained. The review conclusion is: upon review, this product has passed the generic drug quality and efficacy consistency evaluation. This product, as continuation therapy after prior use of Nimodipine Injection, can prevent and treat ischemic neurological damage caused by cerebral vasospasm following aneurysmal subarachnoid hemorrhage. This product can also be used to treat senile cerebral dysfunction, such as: memory impairment, disorientation and attention disorders, and mood swings. Before treatment, it should be determined that these symptoms are not caused by underlying diseases requiring special treatment.